• Building Biotechs
  • Posts
  • How to Build a Lean, Mean Biotech Machine with Bogdan Knezevic, founder of Kaleidoscope Bio

How to Build a Lean, Mean Biotech Machine with Bogdan Knezevic, founder of Kaleidoscope Bio

Plus how to boost your charisma, and News We're Following

Author

Carina Clingman
September 11, 2024

In partnership with

Welcome

The weather here in New England turned a bit crisp last week. 🍁 I’ve been daydreaming of yummy fall foods, snuggly scarves, and operational efficiency. Operational efficiency? Yes, but mostly because of the great conversation I had with Bogdan Knezevic, founder of Kaleidoscope Bio, on that very subject. Check out this week’s podcast to learn more!

What’s inside:

  • NEW EPISODE: How to Build a Lean, Mean Biotech Machine

  • CAREER CORNER: How to boost your charisma!

  • BIOTECH NEWS: Biosecure bill passes, the EY biotech outlook report, Bain raises $3B to fund Life Sci Companies, Candid debuts with $370M, IPO outlook for Zenas and Bicara

The Building Biotechs Podcast

How to Build a Lean, Mean Biotech Machine with Bogdan Knezevic, founder of Kaleidoscope Bio

We chat about optimizing biotech workflows and achieving milestones efficiently. Bogdan shared insights into how companies can better manage research and development processes, reducing operational inefficiencies and saving time, resources, and money.

Career Corner

Boost Your Charisma: How to Attract Jobs and Inspire Others

In this episode, I discuss actionable tips from our recent book club read, 'Captivate,' on how to enhance your charisma for job interviews and networking. I'll share key themes and personal strategies for making a strong first impression, even if you're not naturally charismatic. Learn about the importance of setting up your environment, using body language effectively, and engaging others with genuine interest.

Get a List of the Best HRIS Software for Your Company

  • Get a tailored vendor shortlist based on your unique needs

  • Personalized 1:1 help from HR software expert

  • Save time and money with expert research

Stories We’re Following

House backs bill restricting China role in US biotech

The Biosecure Act, which limits contracts with WuXi AppTec, WuXi Biologics and three other companies, still needs Senate support to advance.

Bain Raises $3B for Fourth Fund to Back Promising Life Sciences Companies

Tuesday’s round brings Bain Capital Life Sciences’ fundraising total to around $6.7 billion since its founding in 2016. Many of its portfolio companies have resulted in high-value exits recently, including Cerevel Therapeutics, Aiolos Bio and Jnana Therapeutics.

Candid, with $370M, sets out to prove bispecifics’ worth in autoimmune disease

The startup believes T cell engagers, rather than cell therapies, will prove the “right horse to bet on” in the race to develop new inflammatory disease treatments, its CEO said.

Zenas BioPharma, Bicara Therapeutics sets IPO price ranges as summer lull ends

Zenas BioPharma Inc. and Bicara Therapeutics Inc. on Friday both set estimated price ranges in their initial public offerings in a sign that the traditional summer lull in deals is coming to an end.

Did someone forward this to you? Wow, you have great friends! Join Our Newsletter to Stay Plugged In.